ABIVAX SA (2X1.DE) Stock Price, Forecast & Analysis
Europe - FRA:2X1 - FR0012333284 - Common Stock
2X1.DE Key Statistics, Chart & Performance
The current stock price of 2X1.DE is 99.1 EUR. In the past month the price increased by 18.82%.
2X1.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 73.6 | 48.58B | ||
| ARGX.BR | ARGENX SE | 74.38 | 49.10B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.27B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.58B | ||
| GLPG.AS | GALAPAGOS NV | 23.64 | 1.74B | ||
| 5CV.DE | CUREVAC NV | 5.22 | 1.02B | ||
| NANO.PA | NANOBIOTIX | N/A | 893.91M | ||
| PHIL.MI | PHILOGEN SPA | 20.35 | 678.37M | ||
| IVA.PA | INVENTIVA SA | N/A | 508.76M | ||
| FYB.DE | FORMYCON AG | N/A | 413.48M | ||
| ALCLS.PA | CELLECTIS | N/A | 358.66M | ||
| AYJ.DE | VALNEVA SE | N/A | 326.14M |
Related stock screener links
About 2X1.DE
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 67
Phone: 33153830963
ABIVAX SA / 2X1.DE FAQ
What does ABIVAX SA do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Can you provide the latest stock price for ABIVAX SA?
The current stock price of 2X1.DE is 99.1 EUR. The price increased by 1.64% in the last trading session.
Does 2X1 stock pay dividends?
2X1.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 2X1 stock?
2X1.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in ABIVAX SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 2X1.DE.
How many employees does ABIVAX SA have?
ABIVAX SA (2X1.DE) currently has 67 employees.
2X1.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 2X1.DE.
2X1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 2X1.DE. Both the profitability and financial health of 2X1.DE have multiple concerns.
2X1.DE Financial Highlights
Over the last trailing twelve months 2X1.DE reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
2X1.DE Forecast & Estimates
14 analysts have analysed 2X1.DE and the average price target is 105.59 EUR. This implies a price increase of 6.55% is expected in the next year compared to the current price of 99.1.
For the next year, analysts expect an EPS growth of -3.38% and a revenue growth 91.53% for 2X1.DE